Background: Previous studies have demonstrated that fibrates have an effect on creatinine concentrations. The pattern of change with fibrates in estimated glomerular filtration rate (eGFR), widely used in clinical practice, has not been previously described.
Methods: Data was retrospectively collected from 132 consecutive case notes of patients started on fibrates in a lipid clinic between 2002 and 2008. Pre- and post-fibrate creatinine concentrations were measured and eGFR measurements were obtained.
Results: Of the 79 patients with both pre and post-treatment eGFR values <90 ml/min/1.73 m(2), a significant mean eGFR reduction of 8.2 ml/min/1.73 m(2) was noted. Of these patients, 50% demonstrated a reduction in eGFR >8 ml/min/1.73 m(2), 25% demonstrated a reduction >16 ml/min/1.73 m(2), and 10% demonstrated a reduction >21 ml/min/1.73 m(2).
Conclusions: The authors demonstrate a significant effect of fibrates on eGFR in clinical practice. Awareness of the pattern of eGFR change is important for decisions regarding the continued use of fibrate therapy and/or commonly co-prescribed diabetic drugs and renal specialist referrals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/postgradmedj-2011-130594 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pemafibrate Induces a Low Level of PPARα Agonist-Stimulated mRNA Expression of ANGPTL4 in ARPE19 Cell.
Bioengineering (Basel)
December 2024
Departments of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.
To elucidate the unidentified roles of a selective peroxisome proliferator-activated receptor α (PPARα) agonist, pemafibrate (Pema), on the pathogenesis of retinal ischemic diseases (RID)s, the pharmacological effects of Pema on the retinal pigment epithelium (RPE), which is involved in the pathogenesis of RID, were compared with the pharmacological effects of the non-fibrate PPARα agonist GW7647 (GW). For this purpose, the human RPE cell line ARPE19 that was untreated (NT) or treated with Pema or GW was subjected to Seahorse cellular metabolic analysis and RNA sequencing analysis. Real-time cellular metabolic function analysis revealed that pharmacological effects of the PPARα agonist actions on essential metabolic functions in RPE cells were substantially different between Pema-treated cells and GW-treated cells.
View Article and Find Full Text PDFComparative Effectiveness of Anti-Hyperlipidemic Drugs Monotherapy in Primary Prevention of Cardiovascular Disease.
Int J Gen Med
October 2024
Pharmacotherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands.
Purpose: Anti-hyperlipidemic drug treatments are effective in reducing the risk of cardiovascular disease. In a long-term retrospective inception cohort study, we aimed to assess the real-world comparative effectiveness of anti-hyperlipidemic monotherapies for primary prevention of cardiovascular events.
Patients And Methods: Patients aged 18 years and older, who initiated primary prevention with anti-hyperlipidemic monotherapy, were selected from the University of Groningen IADB.
Fenofibrate and risk of end-stage renal disease: A nationwide cohort study.
Diabetes Obes Metab
October 2024
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Article Synopsis
- The study investigates the potential renoprotective effects of fenofibrate in preventing or delaying end-stage renal disease in patients already on statins.
- Using data from the Korea National Health Information Database, researchers compared 413,715 fenofibrate users to the same number of non-users, focusing on the incidence of end-stage renal disease.
- Results showed a significantly lower incidence of end-stage renal disease in fenofibrate users, particularly among those with hypertension, proteinuria, or low estimated glomerular filtration rate, suggesting a need for further research through randomized controlled trials.
Use of cholesterol-lowering medications in relation to risk of primary liver cancer in the Clinical Practice Research Datalink.
Cancer
October 2024
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Background: Although the relation between statin use and liver cancer risk has been extensively examined, few studies have examined other cholesterol-lowering medications in relation to liver cancer risk. The authors examined five classes of nonstatin medications and liver cancer risk.
Methods: A nested case-control including 3719 cases and 14,876 matched controls was conducted within the Clinical Practice Research Datalink.
Association of remnant cholesterol with risk of dementia: a nationwide population-based cohort study in South Korea.
Lancet Healthy Longev
August 2024
Department of Internal Medicine, Hallym University College of Medicine, Gangwon-do, South Korea.
Background: The association between remnant cholesterol (remnant-C) and cardiovascular disease risk is well established, but its association with dementia remains unclear. We aimed to examine this association using a large-scale population dataset.
Methods: We did a nationwide, population-based cohort study in which we identified participants aged 40 years and older who underwent the national health examination in 2009 from South Korea's National Health Insurance Service.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!